[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346629-105":59,"doc-detail-346629-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","bioorthogonal-catalytic-centres-engineered-for-gastrointestinal-stabilization-provide-oral-delivery-for-the-treatment-of-gastric-cancer-abstract","Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer - Abstract","","Gastric cancer remains challenging due to late diagnosis, early metastasis, limited surgical options, and systemic chemotherapy toxicity. This study introduces a disulfide-linked thermostable exoshell platform that orally delivers protein-based bioorthogonal catalytic centres, stabilizing them in the harsh gastric environment. Active prodrug metabolites of indole-3-acetic acid (IAA) generated in situ inhibit HER2-independent gastric cancer growth and trigger necroptosis-related markers and mitochondrial effects. Oral dosing in a mouse model reduces inflammation and polyp development, with LC/MS/MS showing increased cytotoxic IAA metabolites and redox-regulatory compounds.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bioorthogonal-catalytic-centres-engineered-for-gastrointestinal-stabilization-provide-oral-delivery-for-the-treatment-of-gastric-cancer-abstract/346629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bioorthogonal-catalytic-centres-engineered-for-gastrointestinal-stabilization-provide-oral-delivery-for-the-treatment-of-gastric-cancer-abstract/346629.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in gastric cancer treatment?","Question",{"text":113,"@type":114},"Gastric cancer is difficult to treat because therapies face late diagnosis, early metastasis, limited surgical options, and chemotherapy-related systemic toxicity. The work targets delivery and localized drug release in the gastrointestinal environment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the proposed exoshell system work?",{"text":118,"@type":114},"The study uses disulfide-linked thermostable exoshells to encapsulate and stabilize labile bioorthogonal catalytic centres for oral delivery. These centres are intended to deliver active catalytic activity directly to cancer tissues.",{"name":120,"@type":111,"acceptedAnswer":121},"What biological effects were observed after treatment?",{"text":122,"@type":114},"In vitro, the approach inhibits gastric cancer cell growth in a dose- and time-dependent manner, regardless of HER2 status. The inhibition is linked to mitochondrial lipid peroxidation, reduced mitochondrial membrane potential, and necroptosis marker activation (RIP1, RIP3, MLKL).",{"name":124,"@type":111,"acceptedAnswer":125},"What did the mouse model and metabolomic analysis show?",{"text":126,"@type":114},"In a mouse model, oral administration of catalytic exoshells for 6 weeks significantly inhibited gastric inflammation and tumour polyp growth. Plasma metabolomics showed upregulation of cytotoxic IAA metabolites and redox-regulatory compounds such as alpha-tocopherol and glutathione-related metabolites.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},346629,1790344030,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Shanmugam etal. Journal of Nanobiotechnology (2026) 24:234  \n[https://doi.org/10.1186/s12951-026-04065-2](https://doi.org/10.1186/s12951-026-04065-2)  \nJournal of Nanobiotechnology  \nRESEARCH Open Access  \nBioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer  \nMuthu Kumaraswamy Shanmugam1,2†, Girish Vallerinteavide Mavelli1†, Pang Yuze1, Hrucha Shielesh Damle 1, Leroy Sivappiragasam Pakkiri1, Lik Hang Wu1,3, Lim Poh Leong1, Siddhesh Sujit Vaidya1, Samira Sadeghi1, Gautam Sethi2 and Chester Lee Drum1*  \nAbstract  \nBackground Gastric cancer, the fifth most prevalent cancer globally, poses significant treatment challenges due to factors such as late diagnosis, early metastasis, limited surgical options, and the systemic toxicity of chemotherapy. Because luminal barriers are often compromised in gastric cancers , orally administered therapies that enable localized absorption and drug release represent a promising new direction for site-specific treatment with limited side effects.  \nResults We introduce a disulfide-linked thermostable exoshell system that orally delivers protein-based bioorthogonal catalytic centres directly to cancer tissues. The highly engineered exoshells effectively encapsulated and stabilized labile catalytic centres, preventing degradation in the harsh gastric environment. In vivo gastric tumors were treated using the anti-cancer properties of active metabolites of the prodrug indole-3-acetic acid (IAA) converted in situ via bioorthogonal catalysis. In vitro cell studies revealed a dose-and time-dependent inhibition of gastric cancer cell growth, irrespective of their HER2 status. This inhibition was accompanied by upregulation of mitochondrial lipid peroxidation, reduced mitochondrial membrane potential, and activation of necroptotic pathway markers such as RIP1, RIP3, and MLKL at both mRNA and protein levels. In a mouse model of gastric cancer induced by N-Methyl-N-Nitrosourea, oral administration of catalytic exoshells for 6 weeks significantly inhibited gastric inflammation and tumour polyp growth. Additionally, LC/MS/MS-based metabolomic analysis of plasma obtained from treated mice showed significant upregulation of cytotoxic metabolites of IAA. Notably, metabolites relevant to redox regulation, including alpha-tocopherol (vitamin E), glutathione (GSH), homocysteine, methyl cysteine, and cysteine sulfinic acid, were identified as the top differentially expressed metabolites, indicating potent suppression of inflammation and tumour growth. Histological analysis of gastric tissue showed a reduced number of polyps and subsequent development of gastric tumours.  \n†Muthu Kumaraswamy Shanmugam and Girish Vallerinteavide Mavelli contributed equally to this work.  \n*Correspondence: Chester Lee Drum [mdccld@nus.edu.sg](mdccld@nus.edu.sg)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026, modified publication (2026). Open Access This article is licensed under a Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://cre](htt","cbCaidmzz0bRe4HU","https://ap.wps.com/l/cbCaidmzz0bRe4HU","pdf",11413761,23,"English","# Abstract\n## Background\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What problem does the study address in gastric cancer treatment?\",\"answer\":\"Gastric cancer is difficult to treat because therapies face late diagnosis, early metastasis, limited surgical options, and chemotherapy-related systemic toxicity. The work targets delivery and localized drug release in the gastrointestinal environment.\"},{\"question\":\"How does the proposed exoshell system work?\",\"answer\":\"The study uses disulfide-linked thermostable exoshells to encapsulate and stabilize labile bioorthogonal catalytic centres for oral delivery. These centres are intended to deliver active catalytic activity directly to cancer tissues.\"},{\"question\":\"What biological effects were observed after treatment?\",\"answer\":\"In vitro, the approach inhibits gastric cancer cell growth in a dose- and time-dependent manner, regardless of HER2 status. The inhibition is linked to mitochondrial lipid peroxidation, reduced mitochondrial membrane potential, and necroptosis marker activation (RIP1, RIP3, MLKL).\"},{\"question\":\"What did the mouse model and metabolomic analysis show?\",\"answer\":\"In a mouse model, oral administration of catalytic exoshells for 6 weeks significantly inhibited gastric inflammation and tumour polyp growth. Plasma metabolomics showed upregulation of cytotoxic IAA metabolites and redox-regulatory compounds such as alpha-tocopherol and glutathione-related metabolites.\"}]","Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer - Abstract | PDF",1790062167,58,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5521174d3496d6f4afaf51100635f457.webp",983,1310,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b23d8d88d993874d00b1d9b9e40c480.webp",982,1309,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce8930f433ff97761ae301f9b530d738.webp",981,1308,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94b4a7935548da9cd479210359d50c26.webp",980,1306]